In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Everything You Need to Know About the FDA Peptide Ban Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida